- Home
- ONCO vs CDIO Comparison
ONCO vs CDIO Comparison
Compare ONCO & CDIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONCO | CDIO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ONCO | CDIO |
|---|---|---|
| Price | $0.83 | $1.34 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 480.1K | 120.9K |
| Earning Date | 11-13-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,223,751.00 | $15,782.00 |
| Revenue This Year | N/A | $1,434.82 |
| Revenue Next Year | N/A | $4,661.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.74 | $0.97 |
| 52 Week High | $47.66 | $20.55 |
Technical Indicators
Market Signals| Indicator | ONCO | CDIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.02 | 31.79 |
| Support Level | $1.15 | $1.20 |
| Resistance Level | $1.86 | $1.51 |
| Average True Range (ATR) | 0.18 | 0.19 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 2.81 | 31.11 |
Price Performance
Historical ComparisonAbout ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.
About CDIO Cardio Diagnostics Holdings Inc.
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.